Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FLT3 exon 14 ins||acute myeloid leukemia||sensitive||Ponatinib||Phase I||Actionable||In a Phase I trial, Iclusig (ponatinib) resulted in a 25% (3/12) overall response rate, indicated as partial remission or better, in acute myeloid leukemia patients harboring FLT3-ITD (PMID: 23691988).||23691988|
|FLT3 exon 14 ins||acute myeloid leukemia||sensitive||Ponatinib||Preclinical - Patient cell culture||Actionable||In a preclinical study, Iclusig (ponatinib) inhibited viability of patient derived acute myeloid leukemia cells harboring FLT3 ITD mutations in culture, and inhibited growth of tumors in cell line xenograft models (PMID: 21482694).||21482694|
|PubMed Id||Reference Title||Details|
|(21482694)||Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.||Full reference...|
|(23691988)||Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study.||Full reference...|